AstraZeneca pays 660% premium for gene therapy firm LogicBio

1 min read
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York, United States

(Reuters) – Shares of LogicBio Therapeutics skyrocketed on Monday after Britain’s AstraZeneca’s said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.

LoigBio’s shares, which have traded below $1 since February, were up 637% at $2 before the bell, close to AstraZeneca’s offer price of $2.07 per share.

LogicBio is developing gene editing therapies to treat pediatric rare disease like methylmalonic acidemia, where the body cannot break down certain proteins and fats.

AstraZeneca said the deal would accelerate growth of its Alexion unit, which it acquired for $39 billion last year, in the field of genomic medicine.


Related News:   Australia deploys more experts, equipment to search for lost radioactive capsule

(Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel)

tagreuters.com2022binary_LYNXMPEI920KM-BASEIMAGE